

Herpes Drug Development Program at NanoViricides Moves Forward; The CBCD Reviews a Report

Topical treatments against the herpes virus require “significantly less development work compared to the development of an injectable drug.” (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, August 27, 2015 /EINPresswire.com/ --

“Infected with a herpes virus? The CBCD recommends taking [Gene-Eden-VIR](#) or [Novirin](#).” - Greg Bennett, CBCD

According to a report, the biotech company NanoViricides, Inc., (NYSE MKT: NNVC) is speeding up its anti-herpes drug development program. The company plans to focus on topical treatments as opposed to oral or injectable drugs. In a statement, the company said that “drug development of the external treatments for the different herpes virus infections, such as topical skin creams or lotions for the treatment of herpes lesions, or shingles rash, as well as eye drops or gels for the treatment of herpes keratitis, are likely to require significantly less development work compared to the development of an injectable drug. “ (1) In press releases, NanoViricides revealed that “its anti-herpes drug candidates have demonstrated excellent efficacy in repeated experiments in a dermal infection model of zosteriform herpes in mice in two different laboratories.” (1) This means that in animal experiments, there have been positive developments against the herpes zoster virus. However, the company has no drugs that are currently on the market against the herpes zoster virus, or any other virus in the herpes family.



The public should be aware that developing an effective, therapeutic drug against the herpes virus (HSV-1 and HSV-2, or other herpes viruses) and gaining FDA

virus, take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was shown to reduce symptoms associated with herpes viruses in two separate post-marketing clinical studies that followed FDA guidelines. In addition, the formula was designed to help the immune system target the latent form of the virus.

Click to learn more about [herpes symptoms](#).

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the formula is effective against the herpes family of viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with HSV-1 or HSV-2 (and other herpes viruses) ... reported a safe decrease in their symptoms following treatment with (the formula of Gene-Eden-VIR and Novirin)." (2) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (2)

Gene-Eden-VIR and Novirin can be ordered online on their product websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims. Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

It should be noted that "At present, there is no cure for herpes and the infection is life-long. Current therapy for HSV-2 involves daily doses of antiviral drugs which can reduce, but not eliminate, outbreaks and viral shedding, so they can only reduce symptoms but are unable to prevent the spread of the virus." (3)

What treatments are currently available for those infected with the herpes virus?

"Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day." (2)

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure. However, two clinical studies, published in peer reviewed medical journals showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was shown to safely

and effectively reduce herpes symptoms. Additionally, it was designed to help the immune system target the latent virus.

“We recommend that individuals who are infected with a latent herpes virus, take Gene-Eden-VIR or Novirin.” – Greg Bennett, CBCD

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) NanoViricides Accelerates its Herpes Drug Development Program - NanoViricides, Inc.

(2) Polansky, H., Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013. <http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VH2qQNKUf90>

(3) proactiveinvestors.com.au - "Admedus moves to second dose of Herpes vaccine" Published June 05, 2015

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.

